How are unknown nucleotides represented in a patent application?
According to MPEP 2412.05(b), unknown nucleotides in patent applications should be represented as follows: Use the symbol “n” to represent any unknown nucleotide in the sequence Further describe the unknown nucleotide in a feature table using the feature key “unsure” The symbol “n” is equivalent to only one residue The MPEP states, “Any “unknown” nucleotide…
Read MoreHow should circular nucleotide sequences be represented in patent applications?
According to MPEP 2412.05(b), circular nucleotide sequences in patent applications should be represented as follows: The applicant must choose the nucleotide in residue position number 1 Numbering is continuous throughout the entire sequence in the 5′ to 3′ direction The last residue position number must equal the total number of nucleotides in the sequence The…
Read MoreWhat symbols should be used to represent nucleotides in a sequence?
According to MPEP 2412.05(b), the symbols for representing nucleotides in a sequence are as follows: Use only lower-case letters Refer to Table 1: List of Nucleotides Symbols in MPEP 2412.03(a) The symbol “t” represents thymine in DNA and uracil in RNA Use the most restrictive ambiguity symbol when appropriate The symbol “n” represents any nucleotide…
Read MoreHow should nucleotide sequences be represented in patent applications?
According to MPEP 2412.05(b), nucleotide sequences in patent applications filed on or after July 1, 2022, must be represented as follows: A single strand, in the 5′ to 3′ direction from left to right Using only lower-case letters The first nucleotide is residue position number 1 Numbering is continuous throughout the sequence As stated in…
Read MoreHow are modified nucleotides described in a patent application?
Modified nucleotides in patent applications are described according to MPEP 2412.05(b) as follows: Represent modified nucleotides as the corresponding unmodified nucleotides (a, c, g, t) when possible Use the symbol “n” for modified nucleotides that cannot be represented by other symbols Further describe modified nucleotides in a feature table using the feature key “modified_base” Use…
Read MoreHow should regions of consecutive modified nucleotides be described in a patent application?
According to MPEP 2412.05(b), regions of consecutive modified nucleotides in patent applications should be described as follows: Describe the region in a feature table as required for a modified nucleotide Modified nucleotides in the region can be jointly described in a single INSDFeature element Provide the most restrictive unabbreviated chemical name or a list of…
Read More